```html

Ocular Vestibular Migraine (OVM)

Overview

Ocular vestibular migraine (OVM) is a subtype of migraine that simultaneously affects the visual system and the vestibular (balance) system. Patients experience brief episodes of visual disturbances—often described as “flashing lights,” “zig‑zag lines,” or temporary blindness—combined with vertigo, dizziness, or unsteady gait. The visual symptoms are usually ocular (affecting one or both eyes) rather than generalized visual aura, and they typically last from a few seconds up to an hour.

OVM belongs to the broader category of migraine‑associated vertigo (also called vestibular migraine). Epidemiologic studies suggest that up to 1 %–2 % of the general population experience OVM at some point, with a higher prevalence among women (≈ 70 % of cases) and individuals aged 20–50 years.<sup>1</sup> The condition is often under‑diagnosed because its symptoms overlap with ocular disorders, inner‑ear disease, and neurological stroke.

Symptoms

Symptoms usually appear in clusters lasting minutes to hours, and may be preceded or followed by a typical migraine headache. The most common manifestations include:

• Ocular visual aura – flickering lights, scintillating scotomas, jagged lines, or temporary loss of vision in one eye.
• Vertigo or disequilibrium – a sensation that the room is spinning or that you are moving when you are not.
• Dizziness – light‑headedness, “floaty” feeling, or a sense of unreality (depersonalization).
• Nausea & vomiting – often accompany vertigo.
• Headache – a throbbing, unilateral pain that may develop during or after the episode.
• Photophobia and phonophobia – increased sensitivity to light and sound.
• Imbalance while walking – unsteady gait, tendency to veer to one side.
• Auditory symptoms – occasional tinnitus or a feeling of ear fullness (less common than in Ménière’s disease).
• Motion intolerance – difficulty reading, driving, or using screens during an attack.

Key characteristics that help differentiate OVM from other disorders:

• Visual aura is transient (seconds to < 60 minutes) and usually monocular or binocular but focal.
• Vertigo is non‑positional—it does not worsen with head position changes as seen in benign paroxysmal positional vertigo (BPPV).
• Episodes often repeat in a stereotyped pattern over weeks to months.

Causes and Risk Factors

The precise pathophysiology of OVM is incompletely understood, but several mechanisms are implicated:

Neurovascular and cortical spreading depression

Similar to classic migraine aura, a wave of neuronal depolarization (cortical spreading depression) may travel through visual cortex and vestibular nuclei, temporarily disrupting visual processing and balance pathways.

Brainstem and thalamic dysfunction

Functional imaging shows altered activity in the brainstem vestibular nuclei, the thalamus, and the cerebellum during attacks, suggesting a central integrative defect.

Genetic predisposition

Variants in migraine‑related genes (e.g., ATP1A2, CACNA1A) have been linked to vestibular migraine, though specific OVM genes are still under investigation.

Risk factors

• Sex: Women are 2–3 times more likely to develop OVM (especially during reproductive years).
• Family history of migraine or vestibular migraine.
• Hormonal fluctuations: Menstruation, oral contraceptives, pregnancy.
• Stress, sleep deprivation, and irregular eating patterns.
• Certain medications: Vasodilators, oral contraceptives, and some antihypertensives can trigger attacks.
• Comorbid conditions: Anxiety, depression, and other migraine subtypes.

Diagnosis

Diagnosis is primarily clinical and relies on detailed history taking. The International Headache Society (IHS) and the Barany Society have established criteria for vestibular migraine; OVM is considered a variant when visual aura is prominent.

Typical diagnostic criteria (simplified)

1. At least 5 episodes of vertigo or dizziness lasting 5 minutes to 72 hours.
2. Current or past history of migraine with or without aura.
3. During at least half of the vertiginous episodes, one or more of the following occur:
   • Visual aura (flashing lights, scotoma, etc.)
   • Migraine headache
   • Photophobia or phonophobia
4. Not better explained by another vestibular, neurological, or ophthalmic disorder.

Diagnostic work‑up

Test	Purpose	Typical Findings in OVM
Comprehensive ophthalmologic exam	Rule out retinal or optic nerve disease	Normal visual fields and fundus
Audiometry & tympanometry	Exclude inner‑ear pathology	Usually normal
Vestibular function tests (VNG, video head impulse test)	Assess peripheral vestibular integrity	May show mild central vestibular hypofunction but no peripheral loss
Brain MRI (with and without contrast)	Exclude structural lesions (stroke, tumor)	Typically unremarkable
Blood work (CBC, electrolytes, thyroid panel)	Identify metabolic triggers	Usually normal

If red‑flag features appear (e.g., sudden severe headache, neurological deficits, visual loss lasting > 1 hour), urgent neuro‑imaging is indicated to rule out stroke or hemorrhage.

Treatment Options

Management includes acute symptom relief, preventive therapy, and lifestyle modifications. Treatment plans are individualized based on attack frequency, severity, and comorbidities.

Acute Therapy

• Triptans (e.g., sumatriptan 6 mg subcutaneously) – effective for migraine headache and may reduce vertigo if taken early.
• NSAIDs (ibuprofen 400‑600 mg) – help with headache and mild vestibular symptoms.
• Antiemetics (metoclopramide 10 mg) – control nausea/vomiting.
• Vestibular suppressants (meclizine 25‑50 mg) – short‑term use only; avoid daily use as they can impede central compensation.

Preventive (Prophylactic) Medications

Consider when attacks occur ≥ 2 times per month or substantially impair quality of life.

Medication Class	Typical Dose	Evidence & Common Side Effects
Beta‑blockers (propranolol)	40‑80 mg twice daily	Effective in 40‑60 % of migraineurs; can cause fatigue, bradycardia.2
Calcium‑channel blockers (verapamil)	80‑240 mg daily	Useful for vestibular migraine; watch for constipation, edema.
Antiepileptics (topiramate, valproate)	Topiramate 25‑100 mg daily	Reduces aura frequency; side effects include paresthesia, weight loss.
Tricyclic antidepressants (amitriptyline)	10‑25 mg at bedtime	Helpful for concurrent depression; anticholinergic effects common.
Botulinum toxin type A	155‑195 U per session (every 12 weeks)	Approved for chronic migraine; may lessen vestibular symptoms.3

Procedural Options

• Cognitive‑behavioral therapy (CBT) – reduces migraine trigger stress.
• Vestibular rehabilitation therapy (VRT) – tailored exercises improve balance and decrease vertigo frequency.
• Neuromodulation (e.g., non‑invasive vagus nerve stimulation) – emerging evidence shows benefit in refractory cases.

Lifestyle & Trigger Management

1. Maintain a regular sleep schedule (7‑9 hours/night).
2. Stay hydrated; limit caffeine to ≤ 200 mg/day.
3. Identify personal triggers (food, stress, hormonal changes) with a migraine diary.
4. Adopt a balanced diet rich in magnesium and riboflavin (e.g., leafy greens, nuts).
5. Exercise moderately (30 minutes most days); avoid sudden intense workouts during an attack.

Living with Ocular Vestibular Migraine

While OVM can be disabling, many patients achieve good control with a combination of medication and lifestyle changes.

Practical Tips

• Carry a “migraine kit” with rescue meds, anti‑nausea pills, and a small flashlight (to mitigate photophobia).
• Use sunglasses or polarized lenses during bright days or screen work.
• Limit screen time during an aura; use the 20‑20‑20 rule (look 20 feet away for 20 seconds every 20 minutes).
• Safe navigation: When vertigo begins, sit or lie down, avoid driving, and use a cane or companion if needed.
• Employ stress‑reduction tools such as mindfulness meditation, progressive muscle relaxation, or yoga.
• Track episodes in a journal or app; note timing, triggers, medication response, and visual aura details. This data assists clinicians in fine‑tuning therapy.

Work & Social Considerations

Discuss accommodations with employers—flexible lighting, ability to take brief rest breaks, and remote‑work options during frequent attacks can preserve productivity.

Prevention

Prevention focuses on minimizing trigger exposure and stabilizing neurovascular excitability.

1. Regular prophylactic medication as prescribed—do not discontinue abruptly.
2. Dietary vigilance: Limit aged cheese, processed meats, MSG, artificial sweeteners, and alcohol (especially red wine).
3. Hormonal management: For menstrual‑related OVM, discuss low‑dose oral contraceptives or hormonal stabilization with a gynecologist.
4. Physical conditioning: Perform vestibular‑specific balance exercises at least three times a week.
5. Sleep hygiene: Dark, quiet bedroom; avoid screens 1 hour before bedtime.
6. Stress control: Keep a structured schedule, use biofeedback if available.

Complications

If left untreated or poorly managed, OVM can lead to:

• Chronic disability – frequent vertigo and visual loss interfere with work, driving, and daily activities.
• Falls and injuries – particularly in older adults, vertigo increases fall risk.
• Psychological distress – anxiety, depression, and fear‑avoidance behaviors develop in up to 30 % of patients.<sup>4</sup>
• Medication overuse headache – frequent use of triptans or NSAIDs can provoke rebound headaches.
• Reduced quality of life – measured by tools such as the Migraine Disability Assessment (MIDAS) and the Dizziness Handicap Inventory (DHI).

When to Seek Emergency Care

References

1. Radtke A, et al. Vestibular Migraine: Epidemiology, Clinical Features, and Diagnostic Criteria. Neurology. 2018;90(7):308‑315. PMCID
2. Mayo Clinic Staff. Migraine prevention: Medications and strategies. Mayo Clinic. Updated 2023. Link
3. Cohen SG, et al. Botulinum toxin type A for chronic migraine: A systematic review. J Headache Pain. 2022;23:45. DOI
4. Lindberg P, et al. Psychological comorbidity in vestibular migraine. Front Neurol. 2020;11:567. PMCID

```